IV vs. shot biologics for IBD: which works better?
Part of Digestive system clinical trials.
This study compares intravenous (IV) and under-the-skin (subcutaneous) biologic drugs for people with Crohn's disease or ulcerative colitis. It helps doctors understand if switching from the IV form to a shot is as effective and well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with Crohn's disease, ulcerative colitis, or indeterminate colitis.
- You are currently receiving vedolizumab or infliximab through an IV, or you switched from IV to a shot of the same drug at least 2 weeks ago.
- Your IBD has been in remission (no active symptoms) for at least 12 weeks without needing steroids.
- You are willing and able to sign a consent form and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This research study tests whether taking vedolizumab injections less often (every 4 weeks instead of every 2 weeks) can still keep your Crohn's or colitis in remission. If you are already well-controlled on standard vedolizumab, this study may help you and others by reducing the number of injections needed.
This study looks at why some people with inflammatory bowel disease (Crohn's or ulcerative colitis) do not respond to certain biologic treatments. Researchers will use advanced testing (multi-omics) to better understand treatment response. If you are starting or have just started treatment with infliximab, adalimumab, vedolizumab, or ustekinumab, you may be able to join.
This study looks at different ways to measure the amount of biologic drugs in your blood. It is for people with inflammatory bowel disease who are about to start a new biologic therapy or have never taken one before.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.